EMERYVILLE, Calif., Oct. 10 NeurobiologicalTechnologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold aconference call on Monday, October 13, to provide an update on theViprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke.Hosting the call will be Paul E. Freiman, president and chief executiveofficer and Warren W. Wasiewski, chief medical officer.
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceuticalcompany focused on developing novel, first-in-class agents for central nervoussystem conditions and other serious unmet medical needs. The Company's mostadvanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinicaltesting as a novel investigational drug for the treatment of acute ischemicstroke. Viprinex has multiple mechanisms of action and is specificallydesigned to extend the time period that patients can be treated after theonset of a stroke. Acute ischemic stroke is one of the most prevalent,debilitating and costly diseases in the world for which there are fewacceptable treatment options. NTI also has early-stage development programsfor Alzheimer's and Huntington's diseases and rights to receive payments on anapproved drug for Alzheimer's disease and an investigational drug in Phase 3trials for brain swelling.-- Date: Monday, October 13, 2008 -- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT) -- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942 International Telephonic Replay: A playback of the conference call will be available from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20, 2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 9164451
SOURCE Neurobiological Technologies, Inc.